Kamau Therapeutics Emerges from Stealth With Clinical-Stage Novel Gene Correction Technology Targeting Life-Threatening Genetic Diseases

Kamau Therapeutics Emerges from Stealth With Clinical-Stage Novel Gene Correction Technology Targeting Life-Threatening Genetic Diseases   San Francisco, December 7, 2023 — Kamau Therapeutics (“Kamau” or “the Company”), a clinical-stage gene correction company, announced today its emergence from stealth, following a strategic transaction with Graphite Bio “Graphite”. Under the terms of the agreement, Kamau received […]